Key Points
- Insider sale: Edwards Lifesciences SVP Andrew Dahl sold 568 shares on May 29 at an average price of $86.08, totaling about $48,893.44. After the sale, he still held 15,334 shares.
- Stock performance and fundamentals: EW shares were up 0.5% and opened at $86.41, near the company’s 52-week high of $88.28. Edwards Lifesciences has a market cap of about $49.76 billion and a low debt-to-equity ratio of 0.06.
- Results and analyst sentiment: The company recently beat quarterly EPS and revenue estimates, with revenue rising 16.7% year over year. Wall Street remains broadly positive, with an average rating of Moderate Buy and an average price target of $95.65.
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) SVP Andrew Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Edwards Lifesciences Stock Up 0.5%
Shares of EW stock opened at $86.41 on Friday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $88.28. The firm's fifty day moving average price is $81.73 and its two-hundred day moving average price is $83.01. The firm has a market capitalization of $49.76 billion, a P/E ratio of 45.96, a PEG ratio of 2.15 and a beta of 0.87.
Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same period in the previous year, the business earned $0.64 EPS. The company's revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have commented on EW. Wolfe Research upgraded shares of Edwards Lifesciences from a "peer perform" rating to an "outperform" rating and set a $92.00 price target for the company in a research note on Wednesday, April 1st. Evercore reiterated an "outperform" rating and issued a $93.00 price target on shares of Edwards Lifesciences in a research note on Friday, April 24th. Weiss Ratings reiterated a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Piper Sandler reiterated an "overweight" rating and issued a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Finally, Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the company a "hold" rating in a research note on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $95.65.
Check Out Our Latest Research Report on Edwards Lifesciences
Institutional Trading of Edwards Lifesciences
A number of hedge funds have recently modified their holdings of EW. Hanson & Doremus Investment Management acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $25,000. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $25,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $26,000. RMG Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $26,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $27,000. Institutional investors and hedge funds own 79.46% of the company's stock.
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
